Associated Papers
Identifying predictive markers of head and neck squamous cell carcinoma in an umbrella trial (KCSG HN 15-16 TRIUMPH trial).
Hwang S et al.
Esmo Open, 2025
40967067 (PubMed )
Supplement: mmc9.xlsx › Arm_____
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
Klocker EV et al.
Npj Breast Cancer, 2025
40775238 (PubMed )
Supplement: 41523_2025_805_MOESM1_ESM.pdf
Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma: Association with Metabolic Tumor Burden Determined with FDG-PET/CT.
Silvoniemi A et al.
Cancers, 2023
37568786 (PubMed )
Supplement: cancers-15-03970-s001.zip › cancers-2472979-supplementary.pdf
Detection of PIK3CA Gene Mutation in Head and Neck Squamous Cell Carcinoma Using Droplet Digital PCR and RT-qPCR.
Borkowska EM et al.
Biomolecules, 2021
Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM et al.
Ebiomedicine, 2020
33096476 (PubMed )
Supplement: mmc2.xlsx › RAIDS_algo_filtering_wLOH_forma
Molecular features of premenopausal breast cancers in Latin American women: Pilot results from the PRECAMA study.
Olivier M et al.
Plos One, 2019
30653559 (PubMed )
Supplement: pone.0210372.s001.xlsx › Table_A
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
Tessitore A et al.
Human Pathology, 2018
PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.
Munari FF et al.
Infectious Agents and Cancer, 2018
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW et al.
Plos One, 2016
26919633 (PubMed )
Supplement: pone.0149405.s010.xlsx › validationset
Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.
Lou H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
Hou MM et al.
Oncotarget, 2014
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Janku F et al.
Cancer Research, 2013
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F et al.
Oncotarget, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Janku F et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2012
Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.
Li X et al.
Pathology Oncology Research : Por, 2012
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
Janku F et al.
Plos One, 2011
Select a paper to view details